Who Paid My Doc
Nader Moaven
Infectious Disease Belleville, NJ Medical Doctor
NPI 1831293174 CMS profile 37692
5 Franklin Ave, Suite 302, Belleville, NJ 07109
General payments
$14,883
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Nader Moaven of Belleville, NJ is reported in the CMS Open Payments database as having received $14,883 across 224 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 90th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $107 | 7 | |
| 2022 | General | $189 | 19 | |
| 2021 | General | $654 | 47 | |
| 2020 | General | $5,379 | 82 | |
| 2019 | General | $8,554 | 69 |
Beside peers
- Nader Moaven
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Nader Moaven were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Nader Moaven | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,554 | $190 | $60–$862 | $163 |
| 2020 | $5,379 | $124 | $32–$606 | $114 |
| 2021 | $654 | $148 | $38–$905 | $132 |
| 2022 | $189 | $166 | $50–$834 | $149 |
| 2023 | $107 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 134 drugsPart D claims
7,987
Drug cost
$1,452,760
Branded share of claims
22.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 131 | $582,411 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 22 | $87,419 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 18 | $74,270 | |
| Ozempic Semaglutide | Brand | 50 | $72,103 | |
| Eliquis Apixaban | Brand | 64 | $67,169 | |
| Isentress Raltegravir Potassium | Brand | 27 | $60,295 | |
| Januvia Sitagliptin Phosphate | Brand | 44 | $57,989 | |
| Jardiance Empagliflozin | Brand | 37 | $43,459 | |
| Vascepa Icosapent Ethyl | Brand | 66 | $37,861 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 50 | $37,559 |
The 10 drugs with the highest cost, of 134 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 38 billing codesPaid by Medicare
$51,987
Medicare patients
152
Services billed
990
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 53% | |
| Arthritis | 43% | |
| Chronic kidney disease | 28% | |
| Ischemic heart disease | 27% | |
| Cancer | 19% | |
| Depression | 17% | |
| Atrial fibrillation | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Pcv20 vaccine im 90677 | Office | 36 | 36 | $9,993 |
| Vaccine for influenza for injection into muscle 90653 | Office | 36 | 36 | $2,946 |
| Sarscv2 vac 30mcg trs-suc im 91320 | Office | 18 | 18 | $2,750 |
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 19 | 19 | $2,717 |
| Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 | Office | 18 | 18 | $544 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
224 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in New Jersey
Keith Gottesdiener
Infectious Disease · Rahway, NJ
Jihad Slim
Infectious Disease · Newark, NJ
Maria Szabela
Infectious Disease · Newark, NJ
Ronald Nahass
Infectious Disease · Hillsborough, NJ
Christopher Lucasti
Infectious Disease · Somers Point, NJ
Spartaco Bellomo
Infectious Disease · Jersey City, NJ
Related records
Infectious Disease in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.